TNKase

Active Ingredient(s): Tenecteplase, TNK-tPA
FDA Approved: * June 2, 2000
Pharm Company: * GENENTECH
Category: Heart (Cardiac)

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

TNKase Overview

Tenecteplase (sold under the trade names TNKase and Metalyse) is an enzyme used as a thrombolytic drug. Tenecteplase is a tissue plasminogen activator (tPA) produced by recombinant DNA technology using an established mammalian cell line (Chinese hamster ovary cells). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of aspa...

Read more TNKase Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tenecteplase

Recent TNKase Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for TNKase: (2 results)

Sorted by National Drug Code

• 50242-038 Tnkase Kit by Genentech, Inc.
• 50242-120 Tnkase Kit by Genentech, Inc.

Other drugs which contain Tenecteplase, TNK-tPA or a similar ingredient: (1 result)

• TENECTEPLASE, TNK-TPA